Eli Lilly's 60% Oral GLP-1 Share Bet: Can Foundayo Really Unseat Novo?

Goldman Sachs' oral GLP-1 outlook puts convenience at the center of Lilly's case

Lilly does not need to redo the injectable fight. The higher-upside contest is narrower: take leadership in the oral segment before the market decides convenience is not a material differentiator. Goldman Sachs projects $13.6 billion of oral GLP-1 share for Lilly's pill, implying 60% of the oral market versus 21% for Novo's pill. If that split holds, Lilly could gain investor attention well before its total reported sales fully catch up.

The near-term commercial edge is not about new chemistry. Foundayo can be taken any time of day without restrictions on food and water, while oral Wegovy has to be swallowed first thing in the morning on an empty stomach, with a 30-minute wait before food or drink. In a treatment category where long-term adherence matters, that kind of friction can shape outcomes.

Why the timing matters now

Foundayo was approved earlier this month, and commercial launch started last week. That shifts the debate from trial design to early commercial behavior. Investors can now start testing whether Lilly's access-friendly setup produces real-world stickiness, rather than waiting for long-term proof.

Lilly's second-mover edge is about reducing friction, not beating Novo in a single trial

Needle fear and routine matter in a mainstream obesity market

Obesity affects 40% of U.S. adults, and up to two-thirds report some level of needle fear. In a market of that size, the practical hurdles to starting and staying on treatment can matter as much as raw efficacy. Lilly's opening is straightforward: remove the part of the routine that makes patients hesitate.

Foundayo can be taken any time of day without restrictions on food and water. Novo's oral Wegovy still carries the more rigid morning-dosing rule. That matters because prior oral GLP-1 experience in diabetes suggests restrictions can limit adoption. The clearest example is Rybelsus: by the end of 2023, it accounted for about 14% of GLP-1 market share in diabetes, even as the injectable Ozempic dominated the class commercially.

Foundayo has a meaningful efficacy signal, but accessibility may be the bigger near-term differentiator

In the ATTAIN-1 program, the highest dose of Foundayo produced an average of 27 pounds of weight loss. That provides a meaningful clinical signal. But Lilly is also leaning into the part of the patient journey that can be controlled at launch: how easy the medicine is to fit into daily life.

Access is part of that design. Foundayo is available through LillyDirect with free home delivery, will move into broad availability through U.S. retail pharmacies and telehealth providers, and is also sold through channels including Amazon Pharmacy. Cash-pay pricing starts at $149 a month, while some insured patients can start for $25 a month. In obesity, where demand is high and insurance coverage can be uneven, that mix can influence who actually starts treatment.

Lilly may be aiming to widen the pool of treated patients

Novo likely has the faster first-month story. Lilly's setup may matter more over a longer horizon. A pill with fewer dosing rules could attract patients who would never start an injection and who might struggle with a pill that requires a morning fast. If that happens, oral GLP-1s may do more than redistribute share within the current user base; they could also expand who feels able to begin treatment.

The main watchpoints are straightforward:

• Does Foundayo show durable adherence once the launch novelty fades?
• Can Lilly turn telehealth, pharmacy availability, and home delivery into repeat fills?
• Will Novo's rollout outside the U.S. limit the impact of Lilly's domestic advantage?

What the market will need to see before Lilly's oral lead looks durable

The bullish case is no longer just theoretical. Now that Foundayo is on the market, the key question is whether Lilly's convenience advantage can hold up against a competitor that already has commercial traction.

What would confirm the thesis

Evidence would come from real-world behavior rather than trial headlines: stable uptake after launch, repeat use over time, and signs that easier dosing and access are translating into sustained prescriptions.

What could break it

Bears have two credible arguments. First, oral Wegovy is already showing strong early uptake, and Novo plans to go "all in" outside the U.S. later this year. If that strategy succeeds, Lilly's U.S.-focused advantage may be less decisive than the current narrative suggests.

Second, the efficacy debate is still unresolved because the drugs haven't been evaluated head-to-head. Novo can point to higher weight loss in its own trials, while Lilly has emphasized convenience and real-world fit. If patients increasingly weigh efficacy more heavily than dosing flexibility once the launch novelty wears off, Lilly's edge becomes harder to defend.

For now, the cleanest test is simple: watch U.S. share stability, renewal behavior, and whether Novo's overseas rollout changes the global balance. Lilly appears to have the better second-mover setup in oral GLP-1s, but the market still needs commercial confirmation.